Jane Street Group LLC Sells 25,869 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Jane Street Group LLC trimmed its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 20.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,216 shares of the company’s stock after selling 25,869 shares during the period. Jane Street Group LLC owned 0.13% of Kura Oncology worth $873,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Virtus ETF Advisers LLC raised its stake in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after buying an additional 3,061 shares during the last quarter. Harbor Advisors LLC bought a new stake in shares of Kura Oncology during the fourth quarter worth approximately $87,000. E Fund Management Co. Ltd. bought a new stake in shares of Kura Oncology during the fourth quarter worth approximately $90,000. Optimize Financial Inc bought a new stake in shares of Kura Oncology during the fourth quarter worth approximately $100,000. Finally, Corient Private Wealth LLC bought a new stake in shares of Kura Oncology during the fourth quarter worth approximately $109,000.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on KURA. Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Monday, April 28th. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Kura Oncology in a report on Tuesday, April 8th. Finally, JMP Securities restated a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a report on Tuesday, April 29th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and an average price target of $24.50.

Kura Oncology Stock Down 9.6%

Kura Oncology stock opened at $5.64 on Friday. The stock has a market capitalization of $488.28 million, a PE ratio of -2.39 and a beta of 0.50. Kura Oncology, Inc. has a twelve month low of $5.41 and a twelve month high of $23.48. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average of $6.30 and a 200-day moving average of $8.45.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to the consensus estimate of $39.08 million. On average, equities research analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.